Tezepelumab COPD Exacerbation study - COURSE

Study identifier:D5241C00001

ClinicalTrials.gov identifier:NCT04039113

EudraCT identifier:2019-001363-67

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 2

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

337

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 30 Jul 2019
Primary Completion Date: 10 Nov 2023
Study Completion Date: 31 Jan 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Amgen

Inclusion and exclusion criteria